
Halozyme Therapeutics (HALO) Stock Forecast & Price Target
Halozyme Therapeutics (HALO) Analyst Ratings
Bulls say
Halozyme Therapeutics Inc is projected to experience revenue growth primarily driven by increased royalty revenues, with a forecasted 23% year-over-year growth in revenues for the first quarter of 2025, amounting to $240 million. The company's strong performance in the fourth quarter was significantly supported by a notable increase in prescription and royalty revenue from partnered products like Darzalex, Phesgo, and Vyvgart Hytrulo, underscoring a robust market demand for its coformulated solutions. Furthermore, ongoing business development efforts aimed at securing new partnership agreements and advancements in clinical programs are expected to yield additional positive catalysts that could enhance the company's market position and financial prospects.
Bears say
Halozyme Therapeutics is facing a challenging financial outlook, highlighted by a projected ~10% decrease in royalties for 1Q25, with historically low first-quarter financials expected to persist due to the timing of product launches and milestone payments. Compounding this concern, Merck's potential strategy to circumvent Halozyme's patents for a subcutaneous version of KEYTRUDA could significantly impact revenue, especially as key patents are set to expire in 2028, increasing competition from biosimilars. Additionally, the company grapples with multiple risks, including commercial uncertainties regarding its flagship product ENHANZE, potential setbacks in clinical data, and partnership vulnerabilities that may lead to long-term dilution for shareholders.
This aggregate rating is based on analysts' research of Halozyme Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Halozyme Therapeutics (HALO) Analyst Forecast & Price Prediction
Start investing in Halozyme Therapeutics (HALO)
Order type
Buy in
Order amount
Est. shares
0 shares